Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis

1. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092.10.1056/NEJMoa1402582Search in Google Scholar

2. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-19.10.1016/j.ejps.2014.02.014Search in Google Scholar

3. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016;118:1021-1040.10.1161/CIRCRESAHA.115.306565Search in Google Scholar

4. Su MY, Lin LY, Tseng YH, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7:991-997.10.1016/j.jcmg.2014.04.022Search in Google Scholar

5. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010;7:1438-1445.10.1016/j.hrthm.2010.04.030Search in Google Scholar

6. Li C, Han R, Kang L, et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis. Sci Rep. 2017;7:40523.10.1038/srep40523Search in Google Scholar

7. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol. 2002;135:961-968.10.1038/sj.bjp.0704539Search in Google Scholar

8. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve. 2006;34:327-334.10.1002/mus.20590Search in Google Scholar

9. Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126:1-11.10.1159/000351179Search in Google Scholar

10. Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail. 2018;20:1385-1391.10.1002/ejhf.1286Search in Google Scholar

11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.10.1056/NEJM197112232852601Search in Google Scholar

12. Baek S, Park SH, Won E, et al. Propensity Score Matching: A Conceptual Review for Radiology Researchers. Korean J Radiol. 2015;16:286-296.10.3348/kjr.2015.16.2.286Search in Google Scholar

13. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321-1360.10.1093/ehjci/jew082Search in Google Scholar

14. Mohammed SF, Redfield MM. Response to Letters Regarding Article, “Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction”. Circulation. 2015;132:e206.10.1161/CIRCULATIONAHA.115.017050Search in Google Scholar

15. Lewis GA, Schelbert EB, Naish JH, et al. Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. Cardiovasc Drugs Ther. 2019.10.1007/s10557-019-06876-ySearch in Google Scholar